Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Merck expands cancer immunotherapy pipeline with $680m Harpoon acquisition

The deal includes a T-cell engager for lung cancer and neuroendocrine tumours

- PMLiVE

World Health Organization prequalifies polio vaccine to protect children

The prequalification status will enable countries to access and use the nOPV2 vaccine

- PMLiVE

Testing antibodies in blood samples could help prevent heart attacks

People with serious atherosclerosis are more likely to have a serious heart or circulatory problem

- PMLiVE

Transforming HCP interactions with a robust omnichannel approach

The traditional one-size-fits-all approach is being replaced by a growing preference for customised content, targeted outreach and meaningful engagement

- PMLiVE

Pfizer’s Talzenna combination receives EC approval for metastatic prostate cancer

Approximately 470,000 new cases of prostate cancer were reported in Europe in 2020

- PMLiVE

Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma

More than 16,700 new cases of melanoma are diagnosed in the UK every year

- PMLiVE

Novo Nordisk announces two new research collaborations for cardiometabolic diseases

The research programmes will develop novel treatments for obesity and MASH

- PMLiVE

‘Click chemistry’ system used to map new class of drug targets in cancer and immunology

The novel tagging system won the Nobel Prize in Chemistry in October 2022

- PMLiVE

MHRA sets out regulatory roadmap to support safe access to medical technology

The new regulations will ensure patients have access to the medical devices they need without delay

- PMLiVE

Building the pharmaceutical team of tomorrow

The top seven future capabilities that every team needs

- PMLiVE

Johnson & Johnson to acquire ADC specialist Ambrx Biopharma for approximately $2bn

The deal includes an ADC candidate in clinical development to treat advanced prostate cancer

- PMLiVE

Novo Nordisk’s once-weekly IcoSema shows promise in phase 3a type 2 diabetes trial

IcoSema showed non-inferiority to daily insulin treatment in reducing blood glucose levels

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links